Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses

Journal of Clinical Neuroscience

Volumn 13, Issue 6, 2006, Pages 636-638

  Chapman, C ^a   Tubridy, N ^a,b   Cook, M J ^c   Mitchell, P J ^a   MacGregor, L R ^a   Lovelock, C ^a   Litewka, L ^c   Sedal, L ^c   Kilpatrick, T J ^a   Butzkueven, H ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cerebral atrophy; Cerebral volume; Methylprednisolone; Multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTI-INFLAMMATORY AGENTS; CEREBRAL CORTEX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 33746005895     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2005.08.012     Document Type: Article

References (10)

1. Chard D.T., Griffin C.M., Parker G.J., et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125 (2002) 327-337
2. Miller D.F., Barkhof F., Frank J.A., et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 25 (2002) 1676-1695
3. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
4. Zivadinov R., Rudick R.A., De Masi R., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 (2001) 1239-1247
5. Rao A.B., Richert N.D., Howard T., et al. Effect of intravenous methylprednisolone on MRI measures of disease activity in RRMS patients before and after interferon beta-1b. Neurology 59 (2002) 688-694
6. Hoogervorst E.L., Polman C.H., and Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high dose intravenous methylprednisolone. Mult Scler 8 (2002) 415-419
7. Lawson J.A., Cook M.J., Vogrin S., et al. Clinical, EEG, and quantitative MRI differences in pediatric frontal and temporal lobe epilepsy. Neurology 58 (2002) 723-729
8. Troiano R., Hafstein M., Ruderman M., et al. Effect of high-dose intravenous steroid administration on contrast enhancing computed tomography scan lesions in multiple sclerosis. Ann Neurol 15 (1984) 257-263
9. Burnham J.A., Wright R.R., Dreisbach J., et al. The effect of high dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 42 (1991) 1349-1354
10. Rang H.P., Dale M.M., Ritter J.M., et al. Pharmacology. 3rd ed. (1995), Churchill Livingstone, New York pp. 438-9